Silk Road Medical (SILK)
(Delayed Data from NSDQ)
$21.74 USD
+1.16 (5.64%)
Updated May 31, 2024 04:00 PM ET
After-Market: $21.76 +0.02 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SILK 21.74 +1.16(5.64%)
Will SILK be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SILK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SILK
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
All You Need to Know About Silk Road Medical (SILK) Rating Upgrade to Buy
SILK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
Silk Road Medical's (SILK) New Launch to Aid Its TCAR Portfolio
Silk Road Medical (SILK) Upgraded to Buy: What Does It Mean for the Stock?
Other News for SILK
Analysts’ Top Healthcare Picks: Silk Road Medical (SILK), Eli Lilly & Co (LLY)
Oppenheimer Reaffirms Their Buy Rating on Silk Road Medical (SILK)
Silk Road Medical price target raised by $2 at Piper Sandler, here's why
Piper Sandler Sticks to Their Hold Rating for Silk Road Medical (SILK)
Bank of America Securities Reaffirms Their Sell Rating on Silk Road Medical (SILK)